Mon, January 22, 2018
Fri, January 19, 2018
Thu, January 18, 2018
Wed, January 17, 2018
Tue, January 16, 2018
Fri, January 12, 2018
Thu, January 11, 2018
Wed, January 10, 2018
Tue, January 9, 2018
Mon, January 8, 2018
Fri, January 5, 2018
Thu, January 4, 2018
Wed, January 3, 2018
Tue, January 2, 2018
Tue, December 26, 2017
Fri, December 22, 2017
Thu, December 21, 2017
Wed, December 20, 2017
Tue, December 19, 2017
Mon, December 18, 2017
Fri, December 15, 2017
Thu, December 14, 2017
Wed, December 13, 2017
Tue, December 12, 2017

Yun Zhong Initiated (SRPT) at Strong Buy and Held Target at $75 on, Jan 4th, 2018


//stocks-investing.news-articles.net/content/201 .. g-buy-and-held-target-at-75-on-jan-4th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Yun Zhong of Janney Montgomery Scott, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $75 on, Jan 4th, 2018.

Yun has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 1 agrees with Yun's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Maintained at Hold with Increased Target to $49 on, Thursday, October 26th, 2017


These are the ratings of the 3 analyists that currently disagree with Yun


  • Debjit Chattopadhyay of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $75 on, Friday, December 1st, 2017
  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Monday, October 2nd, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017

Publication Contributing Sources